February 25, 2026 · Form 4 insider transaction
Bunnage Mark E. sold 620 shares of Vertex Pharmaceuticals Incorporated at $486.35 per share, a transaction worth $301.5K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.